Emerging evidence suggests that modulation of the immune response through inhibition of these kinases, particularly via the cGAS-STING pathway and STAT1/STAT3 transcription factors, which activate a type I interferon response and upregulate PD-L1, contributes to anti-tumor immunity (Sato et al., 2017; Taniguchi et al., 2024). Here, STAT1 is linked to neoplasm.